BeEAM方案用于淋巴瘤患者自体造血干细胞移植预处理的效果及安全性

Efficacy and safety of BeEAM regimen in pretreatment of autologous hematopoietic stem cell transplantation for patients with lymphoma

目的探讨BeEAM(苯达莫司汀+阿糖胞苷+依托泊苷+美法仑)方案在淋巴瘤患者自体造血干细胞移植预处理中的效果及安全性。方法回顾性分析甘肃省人民医院2020年1月至2021年2月采用BeEAM方案预处理后行自体造血干细胞移植的15例淋巴瘤患者的临床资料,评估移植相关不良反应及造血重建情况。结果15例患者预处理过程中,13例发生恶心、呕吐及腹泻等胃肠道不良反应,2例发生低钾血症,1例发生肝功能异常,均为1~2级,无3~4级不良反应。1例患者血小板植入不良,余14例患者均获得造血重建。患者移植后外周血中性粒细胞和血小板植入良好的中位时间分别为10 d(9~14 d)和11 d(9~17 d)。随访至2021年3月,患者均生存。结论BeEAM方案用于淋巴瘤患者自体造血干细胞移植预处理效果较好,不良反应可耐受。

Objective To investigate the efficacy and safety of BeEAM(bendamustine+cytarabine+etoposide+melphalan)regimen in pretreatment of autologous hematopoietic stem cell transplantation for patients with lymphoma.Methods The clinical data of 15 patients with lymphoma who underwent autologous hematopoietic stem cell transplantation after pretreatment with BeEAM regimen from January 2020 to February 2021 in Gansu Provincial Hospital were retrospectively analyzed.The transplant-related adverse reactions and hematopoietic reconstitution were evaluated.Results During the pretreatment process of 15 patients,13 patients had gastrointestinal adverse reactions such as nausea,vomiting and diarrhea,2 patients had hypokalemia,and 1 patient had abnormal liver function,but all of them were grade 1-2,and no grade 3-4 adverse reactions occurred.One patient had poor platelet implantation,and the remaining 14 patients all achieved hematopoietic reconstruction.After transplantation,the median time of peripheral blood neutrophils and platelets good implantation in patients was 10 d(9-14 d)and 11 d(9-17 d),respectively.Until March 2021,all patients were alive during follow-up.Conclusions The efficacy of BeEAM regimen in pretreatment of autologous hematopoietic stem cell transplantation for patients with lymphoma is good,and the adverse reactions are tolerable.